Roth Affirms GenVec (GNVC) at 'Buy'; Novartis Partnership is Entering 'Prime Time'
Tweet Send to a Friend
Roth Capital affirms GenVec (Nasdaq: GNVC) at Buy with a price target of $8 after the company announced that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
